Advertisement

Prolaktin und Brustdrüse

  • F. Peters
  • K. v. Werder

Zusammenfassung

Das humane Prolaktin (PRL) ist ein einkettiges Peptidhormon mit 199 Aminosäuren und 3 Disulfidbrücken (Abb.2-1). Die Molekülmasse beträgt 23.000. Prolaktin und Wachstumshormon („growth hormone“ = GH) haben eine ausgeprägte Interspezieshomologie. Es wird angenommen, dass PRL, GH und das plazentare Laktogen (hPL) sich aus einem primordialen Urgen entwickelt haben. Die Transkription des PRL-Gens, welches auf Chromosom 6 lokalisiert ist, wird durch verschiedene Faktoren reguliert. Ein Transkriptionsfaktor ist Pit-1, der nicht nur die PRL-, sondern auch die GH - und TSH -Genexpression stimuliert.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Berg D., Rjosk H.K., Jänicke F., Werder K. von (1983) Behandlung der hyperprolaktinämischen Amenorrhoe durch pulsatile Gabe von Gonadotropin Releasing-Hormon. Geburtshilfe Frauenheilkd 43: 686–688PubMedCrossRefGoogle Scholar
  2. Besser G.M., Parke L., Edwards C.R.W., Forsyth I.A., McNeilly A.S. (1972) Galactorrhea: Successful treatment with reduction of plasma prolactin lebeIs by Bromergocryptine. BR Med J 3: 669–672PubMedCrossRefGoogle Scholar
  3. Bevan J.S., Webster J., Burke C.W., Scanlon M.F. (1992) Dopamine agonists and tumour shrinkage. Endocr Rev 13: 220–240PubMedGoogle Scholar
  4. Biller B.M.K., Baum H.B.A., Rosenthai D.I., Saxe V.C., Charpie P.M., Klibanski, A. (I992) Progressive trabecular osteopathia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 75: 692–697CrossRefGoogle Scholar
  5. Collier R.J. (1985) Nutrionial, metabolic, and environmental aspects of lactation. In: Larson B.I. (ed) Lactation. Academic Press, New York, pp 80–128Google Scholar
  6. Cooke N.E., Coit D., Shine J., Baxter J.D., Martial, J.A. (1981) Human prolactin, cDNA structural analysis and evolutionary comparisons. J Biol Chem 256: 4007–4016PubMedGoogle Scholar
  7. Delgrange E., Maiter D., Donckier J. (1996) Effects of the dopamine agonist cabergoline in patients with prolactin oma intolerant or resistant to bromocriptine. Eur J Endocrinol 134: 454–456PubMedCrossRefGoogle Scholar
  8. Edwards C.R.W., Forsyth I.A., Besser G.M. (1971) Amenorrhea, galactorrhea and primary hypothyroidism with high circulating levels of prolactin. Br Med J 3: 462–464PubMedCrossRefGoogle Scholar
  9. Erdheim J., Stumme D. (1909) Über die Schwangerschaftsveränderung in der Hypophyse. Beitr Pathol Anat Alig Pathol 46: 1–132Google Scholar
  10. Eversmann T., Eichinger R., Fahlbusch R., Rjosk H-K., Werder K. von (1981) Die Hyperprolaktinämie beim Mann. Schweiz Med Wochenschr 111: 1782–1789PubMedGoogle Scholar
  11. Ferrari C.I., Abs R., Bevan J.S. et aL (1997) Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin Endocrinol 46: 407–413CrossRefGoogle Scholar
  12. Flückiger E., Pozo E. del, Werder K. von (1982) Prolactin, physiology, pharmocology and clinical findings. Monographs on endocrinology. Springer, Berlin Heidelberg New York, vol 23Google Scholar
  13. Frawley L.S., Miller H.A., Betts J., Simpson M.T. (1988) Liver tissue from lactating rats produces a factor which stimulates prolactin release and gene expression. Endocrinology 123: 2014–1018PubMedCrossRefGoogle Scholar
  14. Griffith R.W., Turklj I., Braun P. (1979) Pituitary tumors during pregnancy in mothers treated with bromocriptine. Br J Clin Pharmacol 7: 393–396PubMedCrossRefGoogle Scholar
  15. Hattori N., Ikebuko K., Ishihara T., Moridera K., Hino M., Kurahachi H. (1992) Anormalovulatory woman with hyperprolactinemia: presence of anti-prolactin autoantibody and the regulation of prolactin secretion. Acta Endocr 126: 479–500Google Scholar
  16. Hill P., Wynder E.L., Kumar H., Helman P., Rona G., Kuno K. (1976) Prolactin levels in population at risk for breast cancer. Cancer Res 36: 4102–4106PubMedGoogle Scholar
  17. Holtkamp W., Nagel G.A., Wander H.E., Rauschenecker H.F., Heyden D. (1984) Hyperprolactinemia is an indicator of progressive disease and poor pro gnosis in advanced breast cancer. Int J Cancer 34: 323–328PubMedCrossRefGoogle Scholar
  18. Hytten F.E. (1954) Clinical and chemical studies in human lactation. VI. The functional capacity of the breast. Brit Med J 1:912–915PubMedCrossRefGoogle Scholar
  19. Krupp P., Monka C. (1987) Bromocriptine in pregnancy: safety aspects. Klein Wochenschr 65: 823–827CrossRefGoogle Scholar
  20. Kwa H.G., De Jong-Bakker M., Engelsmann E., Cleton F.J. (1974) Plasma-prolactin in human breast cancer. Lancet 1:433–435PubMedCrossRefGoogle Scholar
  21. Lee P.A., Xenakis T., Winer J., Matsenbaugh S. (1976) Puberty in girls: Correlation of serum levels of gonadotropins, prolactin, androgens, estrogens and progestins with physical changes. J Clin Endocrinol Metab 43: 775–784PubMedCrossRefGoogle Scholar
  22. Lely A.J. van der, Brownell J., Lamberts S.W.J. (1991) The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine. J Clin Endocrinol Metab 72: 1136–1141PubMedCrossRefGoogle Scholar
  23. Musey U.C., Delwood C.C., Musey P.I., Martino-Saltzman D., Preedey J.R.K. (1987) Long-term effect of a first pregnancy on the secretion of prolactin. N Engl J Med 316: 229–234PubMedCrossRefGoogle Scholar
  24. Nicoll C.S., Anderson T.R., Herbert, N.J. & Russell, S.M. (1987) Prolactin, growth factors and cell growth. In: Rillema J. (ed) Actions of prolactin on molecular processes. CR Press, Boca Raton, pp 200–212Google Scholar
  25. Nicoll C.S. (1980) Ontogeny and evolution of prolactin’s functions. Federation Proceedings 39: 2563–2568PubMedGoogle Scholar
  26. Peters F. (1992) Gutartige Erkankungen der Brust. Urban & Schwarzenberg, MünchenGoogle Scholar
  27. Peters F., Leber A. (1998) Prolaktin und Mammakarzinom. In: Braendle W., Schulz K.D. (Hrsg) Hormone und Mammakarzinom. Zuckschwerdt, München, 57–64Google Scholar
  28. Peters F., Schuth W. (1989) Hyperprolactinemia and nonpuerperal mastitis (duct ectasia). J Am Med Ass 261: 1618–1620CrossRefGoogle Scholar
  29. Peters F., Schuth W., Scheurich B., Breckwoldt M. (1984) Serum prolactin levels in patients with fibrocystic breast disease. Obstet Gynec 64: 381–385PubMedGoogle Scholar
  30. Rjosk H-K., Fahlbusch R., Werder K. von (1982) Influence of pregnancies on prolactinomas. Acta Endocrinol (Copenh) 100: 337–346PubMedGoogle Scholar
  31. Rjosk H-K., Fahlbusch R., Werder K. von (1982) Spontaneous development of hyperprolactinaemia. Acta Endocrinol (Copenh) 100: 333–336PubMedGoogle Scholar
  32. Rjosk H-K., Werder K. von, Fahlbusch R. (1976) Hyperprolaktinämische Amenorrhoe. Geburtshilfe Frauenheilk 36: 575–587Google Scholar
  33. Schneeberg N.G., Perlott Wtt., Israel S.L. (1960) Incidence of unsuspected „Sheehan’s syndrome“. J Am Med Ass 172: 70–77CrossRefGoogle Scholar
  34. Shome B., Parlow A.F. (1977) Human pituitary prolactin (hPRL). The entire linear amino acid sequence. J Clin Endocrinol Metab 45: 1112–1115PubMedCrossRefGoogle Scholar
  35. Thorner M.O., Martin W.H., Rogol A.D. et al (1980) Rapid regression of pituitary prolactin omas during bromocriptine treatment. J Clin Endocrinol Metab 51: 438–445PubMedCrossRefGoogle Scholar
  36. Thorner M.O., Perryman R.L., Rogol A.D. et al (1981) Rapid changes of prolactinoma volume after withdrawal and reinstitution of bromocriptine. J Clin Endocrinol Metab 53: 480–483PubMedCrossRefGoogle Scholar
  37. Truong A.T., Duez C., Belayew A., Renard A. (1984) Isolation and characterization of the human prolactin gene. EMBO J 3: 429–437PubMedGoogle Scholar
  38. Vance M.L., Lipper M., Klibanski A., Biller B.M.K., Samaan N.A., Molitch M.E. (1990) Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205-502. Ann Intern Med 112: 668–673PubMedCrossRefGoogle Scholar
  39. Vuh G., Wells J.A. (1995) Prolactin receptor antagonists that inhibit the growth of breast cancer cell lives. J Biol Chem 270: 13133–13137CrossRefGoogle Scholar
  40. Walter L.M., Norman L.E. (1983) Structure and evolution of the growth hormone gene family. Edocr Rev 4: 97–130Google Scholar
  41. Wang D.J., De Stavola B.L., Bulbrook R.D. et al (1988) The permanent effect of reproductive events on blood prolactin levels and its relation to breast cancer risk: a population study of postmenopausal women. Eur J Cancer Clin Oncol 24: 1225–1231PubMedCrossRefGoogle Scholar
  42. Webster J., Piscitelli G., Polli A., Ferrari C.I., Ismail I., Scanlon M.F. (1994) A comparison of cabergoline and bromocriptine in the treatment ofhyperprolactinemic amenorrhea. N Engl J Med 331: 904–909PubMedCrossRefGoogle Scholar
  43. Werder K. von, Müller O.A., Fink U., Gräf K. (1994) Diagnosis and treatment of hyperprolactinemia. In: Imura, H. (ed) The pituitary. Raven, New York, pp 453–489Google Scholar
  44. Werder K. von (1998) Klinische Neuroendokrinologie. Springer Verlag, Berlin Heidelberg New York TokyoCrossRefGoogle Scholar
  45. Werder K. von (1996) Prolactinoma: Clinical findings and endocrinology. In: Landolt A.M., Vance M.L., Reilly P.L. (Eds) Pituitary Adenomas, Churchill & Livingstone, New York, London, pp 111–126Google Scholar
  46. Wilde C.J., Addey C.P., Casey M.J., Blatchford D.R., Peaker M. (1988) Feed-back inhibition of milk secretion: The effeet of a fraction of go at milk on milk yield and composition. Quarterly J Exp Physiol 73: 391–397Google Scholar
  47. Yi Cai W., Alexander J.M., Hedley-Whyte E.T., Scheithauer B.W., Jameson J.L., Zervas N.T., Klibanski A. (1994) Ras mutations in human prolactinomas and pituitary carcinomas. J Clin Endocrinol Metab 78: 89–93CrossRefGoogle Scholar
  48. Zargar A.H., Masoodi S.R., Laway B.A., Shah N.A., Salahudin M. (1997) Familial puerperal alactogenesis: possibility of a genetically transmitted isolated prolactin deficiency. Brit J Obstet Gynaecol 104: 629–631CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2001

Authors and Affiliations

  • F. Peters
  • K. v. Werder

There are no affiliations available

Personalised recommendations